Study: ALS Diagnosis Linked to Metals in Blood, Urine
People with higher levels of metals found in their blood and urine may be more likely to be diagnosed with—and die from—ALS, a new study suggests.
People with higher levels of metals found in their blood and urine may be more likely to be diagnosed with—and die from—ALS, a new study suggests.
Scientists discovered two potential methods for preserving diseased neurons that would normally be destroyed by ALS.
Removing ALS patients’ own dysfunctional cells, fixing them, then putting them back in patients’ bodies is safe and well-tolerated, per study.
The genetic fingerprint of five microRNA sequences in blood samples accurately discriminated between people with ALS and healthy individuals.
Read MoreApolipoprotein B-100 is an agent responsible for causing permanent motor disability, motor neuron degeneration, and other pathology in ALS.
Read MoreNon-motor symptoms such as pain, fatigue, and sleep disorders, are observed in patients with ALS and reduce their quality of life.
Read MoreA gene therapy approach, developed at UC San Diego, measurably delayed disease onset in humanized mouse and rat models of familial ALS.
Read MoreEverythingALS announces NeuroSense Therapeutics Ltd as a new collaborator in the effort to identify treatments and a cure for ALS.
Read MoreNeuroSense and NeuraLight collaborate to advance the science of digital biomarkers in the detection and monitoring of ALS.
Read MoreNew Stage III biomarker data in people with ALS validates NeuroSense’s clinical strategy, the company reports.
Read MoreThe immune system may play a fundamental role along with the central nervous system in ALS, Mount Sinai researchers report.
Read MoreIn JAMA Neurology, researchers outline preliminary research that could pave the way for a future test for earlier diagnosis of ALS.
Read MoreResearchers have identified a relationship between the patterns of ALS symptoms and microscopic changes in the brain and spinal cord.
Read MoreStealth BioTherapeutics Corp presents SBT-272 preclinical data demonstrating improvement in upper neuron function in ALS.
Read MoreThe Muscular Dystrophy Association will honor Major League Baseball’s recognition of Lou Gehrig Day at games across the country in June.
Read MoreTeam Gleason and Synchron announce a partnership agreement to provide patient-focused feedback on their platform to transform daily life.
Read MoreSilence ALS initiative will offer an integrated solution to identify, support and potentially treat nano-rare ALS patients.
Read MoreProMIS Neurosciences Inc announces new milestones in potential therapeutic approaches for ALS, the company notes in a media release.
Read More